natrilix sr tablet
servier laboratories south africa (pty) ltd - tablet - see ingredients - each tablet contains indapamide 1,5 mg
coversyl plus tablet
servier laboratories south africa (pty) ltd - tablet - see ingredients - each tablet contains indapamide 1,25 mg perindopril 4,0 mg
prexum tablet
servier laboratories south africa (pty) ltd - tablet - see ingredients - each tablet contains perindopril 4,0 mg
coversyl 5 mg plus tablet
servier laboratories south africa (pty) ltd - tablet - see ingredients - each tablet contains indapamide 1,25 mg perindopril arginine 5,0 mg
biocoversyl plus 10/2,5 tablet
servier laboratories south africa (pty) ltd - tablet - see ingredients - each tablet contains indapamide 2,5 mg perindopril arginine 10,0 mg
coversyl arginine 5mg tablets
servier laboratories ltd - perindopril arginine - oral tablet - 5mg
natrilix 2.5mg tablets
servier laboratories ltd - indapamide hemihydrate - oral tablet - 2.5mg
diamicron 80mg tablets
servier laboratories ltd - gliclazide - oral tablet - 80mg
ardix gliclazide 60 mg mr gliclazide 60 mg tablet blister pack
servier laboratories (aust) pty ltd - gliclazide, quantity: 60 mg - tablet, modified release - excipient ingredients: magnesium stearate; lactose monohydrate; colloidal anhydrous silica; maltodextrin; hypromellose - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose. during controlled clinical trials in patients with type ii diabetes, a modified release formulation of gliclazide (30 mg-120 mg), taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.
diamicron 60 mg mr gliclazide 60 mg tablet blister pack
servier laboratories (aust) pty ltd - gliclazide, quantity: 60 mg - tablet, modified release - excipient ingredients: lactose monohydrate; magnesium stearate; maltodextrin; hypromellose; colloidal anhydrous silica - type ii diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose. during controlled clinical trials in patients with type ii diabetes, a modified release formulation of gliclazide (30 mg-120 mg), taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of hba1c.